A recombinant chimeric plasminogen activator with high affinity for fibrin has increased thrombolytic potency in vitro and in vivo.
Authors:
- 15 November 1991
- journal article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 88 (22) , 10337-10341
Abstract
A recombinant plasminogen activator with high fibrin affinity and specificity was expressed by transfecting hybridoma cells with a plasmid that combines sequence coding for low molecular mass (32 kDa) single-chain urokinase-type plasminogen activator [scuPA(32kDa)] and anti-fibrin monoclonal antibody 59D8. The expression of the recombinant molecule [r-scuPA(32kDa)-59D8] was optimized by replacing the 3' untranslated region (initially that of high molecular mass scuPA) in the plasmid with the 3' untranslated region of either beta-globin or mouse immunoglobulin. This modification resulted in a greater than 100-fold improvement in the level of protein expression. The 103-kDa r-scuPA(32kDa)-59D8 protein displayed catalytic activity indistinguishable from that of high molecular mass scuPA and fibrin binding comparable to that of native antibody 59D8. r-scuPA(32kDa)-59D8 was 6 times more potent than high molecular mass scuPA in lysing a human plasma clot in vitro and was 20 times more potent than high molecular mass scuPA in the rabbit jugular vein model of thrombolysis. Molecules of this type may serve as prototypes for highly specific, antibody-targeted enzymes suitable for human use.Keywords
This publication has 21 references indexed in Scilit:
- Biochemical properties of conjugates of urokinase‐type plasminogen activator with a monoclonal antibody specific for cross‐linked fibrinEuropean Journal of Biochemistry, 1989
- Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarction.BMJ, 1988
- Tissue Plasminogen ActivatorNew England Journal of Medicine, 1988
- Thrombolytic Therapy: Current StatusNew England Journal of Medicine, 1988
- Conjugation to an antifibrin monoclonal antibody enhances the fibrinolytic potency of tissue plasminogen activator in vitroBiochemistry, 1988
- A multicenter, randomized, placebo-controlled trial of a new form of intravenous recombinant tissue-type plasminogen activator (activase) in acute myocardial infarctionJACC, 1987
- Monoclonal Antibodies to a Synthetic Fibrin-Like Peptide Bind to Human Fibrin But Not FibrinogenScience, 1983
- Thrombolysis with Human Extrinsic (Tissue-Type) Plasminogen Activator in Rabbits with Experimental Jugular Vein Thrombosis. EFFECT OF MOLECULAR FORM AND DOSE OF ACTIVATOR, AGE OF THE THROMBUS, AND ROUTE OF ADMINISTRATIONJournal of Clinical Investigation, 1983
- A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye BindingAnalytical Biochemistry, 1976
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Nature, 1970